Clinical trials: Hematopoietic
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Treosulfan-based Conditioning for Transplantation in AML/MDS
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan, will reduce toxicity after allogeneic transplantation while improving myeloablation and and disease control in patients with…
- Trial name
- NCT00491634
- Testing
- treosulfan
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Dr. Avichai Shimoni MD
Gaucher's Disease
Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells
Gaucher's disease is a lysosomal storage disease resulting from glycocerebroside GLUCOCEREBROSIDE (1) accumulation in macrophages due to a genetic deficiency of the enzyme glucocerebrosidase. It may occur in patients of all ages.
- Trial name
- NCT00001234
- Testing
- human glucocerebrosidase cDNA
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Allogeneic Hematopoietic Stem Cell Transplantation
Humor Therapy and Distress After Allogeneic Stem Cell Transplantation
This research study evaluates the impact of a humor intervention on distress (primary outcome), hope, depressive symptoms, anxiety, and pain (secondary outcomes) in patients undergoing allogeneic hematopoietic stem cell…
- Trial name
- NCT03593161
- Testing
- Humor therapy
- Where
- Germany
- Volunteers
- 126 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Leukemia
Interferon α for the Therapy of Minimal Residual Disease
This study aimed to evaluate the efficacy of interferon α among patients undergone unmanipulated blood and marrow transplantation following day 60 post-transplantation who were minimal residual disease positive after…
- Trial name
- NCT02185261
- Testing
- Interferon Alfa-2b
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Peking University People's Hospital
Ionizing Radiation Exposure
Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)
The objective of the study is to evaluate the safety of intramuscular (IM) administration of PLX-R18 in subjects exposed to ionizing radiation and who are at risk of developing HS-ARS.
- Trial name
- HS-ARS (NCT03797040)
- Testing
- Cell therapy
- Volunteers
- 27 people
- Sponsor
- Pluristem Ltd.
Lysosomal Storage Diseases, Cystinosis
Stem Cell Gene Therapy for Cystinosis
This study is a Phase 1/2 clinical trial that will assess the safety and efficacy of enriched gene-corrected hematopoietic stem cells isolated from patients affected with cystinosis.
- Trial name
- NCT03897361
- Testing
- CTNS-RD-04 (including CTNS-RD-04-LB manufactured with LentiBOOST)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Diego
Hematologic Malignancies, Nonmalignant Diseases
Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)
Fludarabine and clofarabine are chemotherapy drugs used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of clofarabine and…
- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies
- Trial name
- NCT03609814
- Testing
- Clofarabine, Fludarabine Injection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Acute Myelogenous Leukemia
Selecting a Favorable KIR Donor in Unrelated HCT for AML
Donors with favorable KIR B haplotype gene content have yielded reduced relapse risk and improved leukemia free survival (LFS) in retrospective analyses of unrelated donor (URD) hematopoietic cell transplantation (HCT) for acute…
- Trial name
- NCT01288222
- Testing
- KIR genotype
- Where
- 19 sites in United States
- Volunteers
- 506 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Non Hodgkin Lymphoma, Hodgkin Lymphoma
Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with…
- Trial name
- NCT01079013
- Testing
- treosulfan
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Allogeneic Haematopoietic Stem Cell Transplantation, Malignant Hematologic Disease
Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelin
This study is a prospective, multicenter, randomized controlled clinical trial planned to enroll 64 female patients with malignant hematologic diseases aged 14-50 years who are scheduled to undergo allogeneic hematopoietic stem…
- Conditions
- Allogeneic Haematopoietic Stem Cell Transplantation, Malignant Hematologic Disease, Ovarian Insufficiency
- Trial name
- NCT07552480
- Testing
- Goserelin
- Where
- 5 sites in China
- Volunteers
- 64 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Oral Disease, Graft-versus-host-disease
Prevalence of Chronic Oral Graft Versus Host Disease Risk Factors in Pediatric Patients
our aim is estimating the Prevalence and predicting risk factors for developing chronic oral graft versus host disease in pediatric patients subjected to hematopoietic stem cells transplantation
- Conditions
- Oral Disease, Graft-versus-host-disease, Stem Cell Transplant Complications, Pediatric Disorder
- Trial name
- NCT03880214
- Volunteers
- 250 people
- Sponsor
- yasmeen magdi sholkamy
Multiple Sclerosis, Relapsing-Remitting
Maximizing Outcome of Multiple Sclerosis Transplantation
Randomized study of autologous un-manipulated peripheral blood hematopoietic stem cell transplant (HSCT) comparing two regimens: (1) cyclophosphamide and rabbit anti-thymoglobulin (rATG) versus (2) cyclophosphamide, rATG, and…
- Trial name
- MOST (NCT03342638)
- Testing
- Cyclophosphamide, Mesna, rATG
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Northwestern University
Thrombocytopenia, Stem Cell Transplant Complications
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
In this study, investigators aim to evaluate the efficacy of avatrombopag in thrombocytopenic patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) through a prospective, multi-center, double-blinded…
- Trial name
- Haplo-HSCT (NCT06202625)
- Testing
- avatrombopag
- Where
- 14 sites in China
- Volunteers
- 142 people
- Sponsor
- Peking University People's Hospital
Leukemia, Lymphoma
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Background: After an allogeneic hematopoietic stem cell transplant (HSCT), the donor genome is found in the recipient s circulation and tissues.
- Conditions
- Leukemia, Lymphoma, Hematologic Malignancy
- Trial name
- NCT06856226
- Testing
- Arm 1
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Infections, Central Nervous System Complication
Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation
All patients undergoing allogeneic or autologous HSCT at the participating centres will be observed. Once a diagnosis of CNS disorder is made, additional data will be reported for these patients.
- Conditions
- Central Nervous System Infections, Central Nervous System Complication, Infectious Disease of Nervous System, Blood Disease
- Trial name
- NCT04737785
- Where
- 22 sites in Australia, Colombia and 10 more
- Volunteers
- 252 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I trial studies the best dose and side effects of NY-ESO-1 T cell receptor (TCR) engineered T cells and how well they work with NY-ESO-1 TCR engineered hematopoietic stem cells (HSCs) after melphalan conditioning…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Fallopian Tube Carcinoma
- Trial name
- NCT03691376
- Testing
- Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Roswell Park Cancer Institute
Combined Immunodeficiencies
Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID)
The purpose of this study is to evaluate selective depletion of naïve CD45RA+ T cells from allogenic peripheral blood stem cell graft in children transplanted for combined immune deficiency.
- Trial name
- CD45RA (NCT02737384)
- Testing
- Depletion in CD45RA graft donor
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Graft vs Host Disease
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
The objectives of this study are to determine the efficacy and safety of BEGEDINA® in subjects with steroid resistant acute graft versus host disease (GvHD).
- Trial name
- NCT02411084
- Testing
- Begelomab, Conventional Second-line Treatment
- Where
- 27 sites in United States, France and 5 more
- Volunteers
- 36 people
- Sponsor
- Adienne SA
Hematological Malignancy
PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
The aim of this trial is to evaluate the efficacy of GVH prophylaxis reinforced by low-dose Thymoglobulin administered at the end of aplasia after haploidentical allogeneic transplantation.
- Trial name
- CASPER (NCT06066255)
- Testing
- Thymoglobulin Injectable Product
- Volunteers
- 27 people
- Sponsor
- Institut Paoli-Calmettes
Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
This phase II trial studies how well ibrutinib or idelalisib works in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma that is persistent or has returned (relapsed) after…
- Conditions
- Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT02662296
- Testing
- Ibrutinib, Idelalisib
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.